Literature DB >> 24946068

Letter: estimating the cost-neutral price of sofosbuvir-based triple therapy for the treatment of naïve patients with genotype 1 HCV infection in Italy.

A Messori1, D Maratea, V Fadda, S Trippoli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24946068     DOI： 10.1111/apt.12823

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN： 0269-2813            Impact factor:   8.171


× No keyword cloud information.
  3 in total

1.  Criteria for Drug Pricing: Preliminary Experiences with Modeling the Price-Volume Relationship.

Authors:  Andrea Messori
Journal:  Sci Pharm       Date:  2015-08-27

2.  Drug Pricing Evolution in Hepatitis C.

Authors:  Nathalie Vernaz; François Girardin; Nicolas Goossens; Urs Brügger; Marco Riguzzi; Arnaud Perrier; Francesco Negro
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

3.  Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation.

Authors:  Giovanni Cenderello; Stefania Artioli; Claudio Viscoli; Ambra Pasa; Mauro Giacomini; Barbara Giannini; Chiara Dentone; Laura Ambra Nicolini; Giovanni Cassola; Antonio Di Biagio
Journal:  Clinicoecon Outcomes Res       Date:  2015-12-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.